PS
BMRN icon

Paul Singer’s BioMarin Pharmaceuticals BMRN Stock Holding History

Paul Singer’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,500,338
Closed -$247M – 33
2025
Q1 		$247M Hold
3,500,338
– – 1.63% 9
2024
Q4 		$230M Hold
3,500,338
– – 1.38% 14
2024
Q3 		$246M Hold
3,500,338
– – 1.27% 15
2024
Q2 		$288M Hold
3,500,338
– – 1.66% 14
2024
Q1 		$306M Buy
3,500,338
+500,000
+17% +$44.8M 1.9% 13
2023
Q4 		$289M Buy
+3,000,338
New +$265M 1.55% 17

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Paul Singer's BMRN Position: Q2 2025 in Review

Paul Singer sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 3,500,338 shares — an estimated $247M sold.

Paul Singer first reported a position in BMRN in Q4 2023 and held it in 6 quarters. The position peaked at $306M in Q1 2024. 582 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Paul Singer reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Paul Singer sold 3,500,338 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $247M.
  • Paul Singer first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 6 quarters.
  • Paul Singer's BioMarin Pharmaceuticals position peaked at $306M in Q1 2024.
  • 582 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Elliott Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.